Eli Lilly jumps as $7.8B Centessa deal boosts sleep-disorder pipeline outlook
Eli Lilly shares are rising after the company agreed to buy Centessa Pharmaceuticals in a deal valued up to about $7.8 billion. The transaction adds Centessa’s orexin receptor 2 (OX2R) sleep-disorder drug pipeline and has triggered a fresh round of bullish analyst commentary.
1. What’s moving the stock today
Eli Lilly is moving higher as investors digest the company’s newly announced agreement to acquire Centessa Pharmaceuticals. The deal is structured at $38.00 per share in cash plus a non-transferable contingent value right that can lift total consideration to $47.00 per share, putting the transaction’s potential value at roughly $7.8 billion and expanding Lilly’s reach in sleep and neuroscience therapies. (investing.com)
2. Why the market likes it
The acquisition delivers a differentiated sleep-disorder pipeline centered on orexin receptor 2 (OX2R) agonists, an area investors increasingly view as a high-value frontier in neuroscience with potential beyond narcolepsy. Strategically, the deal signals Lilly is deploying capital to diversify its growth drivers while maintaining momentum in its core metabolic portfolio. (bioworld.com)
3. What to watch next
Key swing factors include the timeline to close (expected in the second half of 2026), the probability-weighted value of the CVR milestones, and how quickly Lilly can integrate development plans to accelerate late-stage studies. Investors will also be watching whether the deal prompts competitive responses in the orexin space and how sell-side price targets and estimates adjust as models incorporate the new pipeline optionality. (bioworld.com)